1
|
Microneedle patch as a new platform to effectively deliver inactivated polio vaccine and inactivated rotavirus vaccine. NPJ Vaccines 2022; 7:26. [PMID: 35228554 PMCID: PMC8885742 DOI: 10.1038/s41541-022-00443-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2021] [Accepted: 01/20/2022] [Indexed: 11/22/2022] Open
Abstract
We recently reported a lack of interference between inactivated rotavirus vaccine (IRV) and inactivated poliovirus vaccine (IPV) and their potential dose sparing when the two vaccines were administered intramuscularly either in combination or standalone in rats and guinea pigs. In the present study, we optimized the formulations of both vaccines and investigated the feasibility of manufacturing a combined IRV-IPV dissolving microneedle patch (dMNP), assessing its compatibility and immunogenicity in rats. Our results showed that IRV delivered by dMNP alone or in combination with IPV induced similar levels of RV-specific IgG and neutralizing antibody. Likewise, IPV delivered by dMNP alone or in combination with IRV induced comparable levels of neutralizing antibody of poliovirus types 1, 2, and 3. We further demonstrated high stability of IRV-dMNP at 5, 25, and 40 °C and IPV-dMNP at 5 and 25 °C, and found that three doses of IRV or IPV when co-administered at a quarter dose was as potent as a full target dose in inducing neutralizing antibodies against corresponding rotavirus or poliovirus. We conclude that IRV-IPV dMNP did not interfere with each other in triggering an immunologic response and were highly immunogenic in rats. Our findings support the further development of this innovative approach to deliver a novel combination vaccine against rotavirus and poliovirus in children throughout the world.
Collapse
|
2
|
Wang Y, Zade J, Moon SS, Weldon W, Pisal SS, Glass RI, Dhere RM, Jiang B. Lack of immune interference between inactivated polio vaccine and inactivated rotavirus vaccine co-administered by intramuscular injection in two animal species. Vaccine 2019; 37:698-704. [PMID: 30626530 DOI: 10.1016/j.vaccine.2018.12.043] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2018] [Revised: 12/12/2018] [Accepted: 12/16/2018] [Indexed: 11/27/2022]
Abstract
A parenteral inactivated rotavirus vaccine (IRV) in development could address three problems with current live oral rotavirus vaccines (ORV): their lower efficacy in low and middle-income countries (LMICs), lingering concerns about their association with intussusception, and their requirement for a separate supply chain with large volume cold storage. Adding a new parenteral IRV to the current schedule of childhood immunizations would be more acceptable if it could be combined with another injectable vaccine such as inactivated polio vaccine (IPV). Current plans for polio eradication call for phasing out oral polio vaccine (OPV) and transitioning to IPV, initially in LMICs as a single dose booster after two doses of OPV and ultimately as a two dose schedule. Today in many LMICs, IPV is administered as a standalone vaccine, which involves a separate cold chain and is relatively costly. We therefore tested in two animal models formulations of IPV with IRV to determine whether co-administration might interfere with the immune response to each product and spare antigen dose for both vaccines. Our results demonstrate that IRV when adjuvanted with alum and administered alone or in combination with IPV did not impair the immune responses to either rotavirus or poliovirus serotypes 1, 2 and 3. Similarly, IPV when formulated and administered alone or together with IRV induced comparable levels of neutralizing antibody to poliovirus type 1, 2 and 3. Furthermore, comparable antibody titers were observed in animals vaccinated with low, middle or high dose of IPV or IRV in combination. This dose sparing and the lack of interference between IPV and IRV administered together represent another step to support the further development of this novel combination vaccine for children.
Collapse
Affiliation(s)
- Yuhuan Wang
- Division of Viral Diseases, Centers for Diseases Control and Prevention, Atlanta, GA, United States
| | | | - Sung-Sil Moon
- Division of Viral Diseases, Centers for Diseases Control and Prevention, Atlanta, GA, United States
| | - William Weldon
- Division of Viral Diseases, Centers for Diseases Control and Prevention, Atlanta, GA, United States
| | - S S Pisal
- Serum Institute of India Pvt. Ltd., Pune, India
| | - Roger I Glass
- Division of Viral Diseases, Centers for Diseases Control and Prevention, Atlanta, GA, United States; Fogarty International Center, National Institutes of Health, Bethesda, MD, United States
| | | | - Baoming Jiang
- Division of Viral Diseases, Centers for Diseases Control and Prevention, Atlanta, GA, United States.
| |
Collapse
|
3
|
Schiøler KL, McCarty CW. Vaccines for preventing dengue infection. Hippokratia 2016. [DOI: 10.1002/14651858.cd004613.pub2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Karin L Schiøler
- University of Copenhagen; Dept. of Public Health; CSS, Øster Farimagsgade 5 Copenhagen Denmark DK-1014
| | | |
Collapse
|
4
|
López A, Montané E. [Practical aspects for the assessment of clinical trials with prophylactic vaccines against infectious diseases]. Med Clin (Barc) 2010; 135:707-12. [PMID: 20951394 DOI: 10.1016/j.medcli.2010.09.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2010] [Accepted: 09/23/2010] [Indexed: 10/18/2022]
Affiliation(s)
- Anna López
- Fundació Institut per a la Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Barcelona, España.
| | | |
Collapse
|
5
|
Gao G, Wang Q, Dai Z, Calcedo R, Sun X, Li G, Wilson JM. Adenovirus-based vaccines generate cytotoxic T lymphocytes to epitopes of NS1 from dengue virus that are present in all major serotypes. Hum Gene Ther 2008; 19:927-36. [PMID: 18788905 DOI: 10.1089/hum.2008.011] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Dengue virus (DENV) infection is an expanding global threat to public health. Effective vaccine and treatment approaches remain elusive. B cell-directed vaccines may be complicated by an antibody-dependent enhancement (ADE) phenomenon based on cross-serotype, nonneutralizing antibodies. We hypothesized that a CD8(+) T cell-directed genetic vaccine that targets a DENV nonstructural protein, NS1, could be a potential strategy to overcome the ADE barrier and accomplish cross-serotype protection. We selected an adenovirus-based vector as the dengue vaccine carrier. To bypass preexisting immunity to human adenoviruses and to improve vaccine efficacy, we created vaccine vectors, based on simian adenoviruses SAdV22 and SAdV25 as well as human adenovirus serotype 5, expressing the NS1 antigen of the Hainan strain, DENV serotype 2. An NS1 peptide library was screened to identify the immunodominant and functional epitope within the NS1 protein for H-2(d)-restricted CD8(+) T cells in BALB/c mice, using interferon-gamma enzyme-linked immunospot and intracellular cytokine-staining assays. Our study identified the 9-mer AGPWHLGKL (NS1(265273)) as the H-2(d)-restricted T cell epitope whose sequence is highly conserved among 26 strains of DENV serotypes 1, 2, 3, and 4, suggesting potential cross-serotype protection of NS1-directed genetic vaccines in the BALB/c model of DENV infection. Importantly, we characterized the cytokine profile of CD8(+) NS1-specific T cells in BALB/c mice vaccinated with HAdV-5-NS1, SAdV-22-NS1, and SAdV-25 NS1 and demonstrated the effective in vivo cytolytic killing capacity of CD8(+) T cells from SAdV-25-NS1-vaccinated mice.
Collapse
Affiliation(s)
- Guangping Gao
- Vaccine Research Institute, Sun Yat-Sen University, Guangzhou, 510630, China
| | | | | | | | | | | | | |
Collapse
|
6
|
Ahmed A, Al-Olayan E, Amoudy M. Enhancing the Humoral and Melanization Responses of Aedes aegypti Mosquito: A Step Towards the Utilization of Immune System Against Dengue Fever. ACTA ACUST UNITED AC 2008. [DOI: 10.3923/je.2008.305.321] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
7
|
Gao G, Wang Q, Dai Z, Calcedo R, Sun X, Li G, Wilson JM. ADENOVIRUS BASED VACCINES GENERATE CYTOTOXIC T LYMPHOCYTES TO EPITOPES OF NS1 FROM DENGUE VIRUS THAT ARE PRESENT IN ALL MAJOR SEROTYPES. Hum Gene Ther 2008. [DOI: 10.1089/hgt.2008.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
8
|
Chen T, He XX, Peng SH, Lin JS, Chang Y, Liu LF. In vitro effects of a novel nucleoside analog beta-LPA against hepatitis B virus. Shijie Huaren Xiaohua Zazhi 2008; 16:1110-1113. [DOI: 10.11569/wcjd.v16.i10.1110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To explore the in vitro effects of a novel nucleoside analog (β-LPA) against hepatitis B virus (HBV).
METHODS: HepG2.2.2.15 cells were cultured and treated with various concentrations of β-LPA. Serum HBsAg and HBeAg were determined by enzyme-linked immunosorbent assay (ELISA). Intracelluar DNA was extracted and subjected to Southern blotting, hybridized with 32P-labeled HBV probe and autoradiographed. The intensity of the autoradiographic bands was quantified by densitometric scans of computer and ED50 value was calculated. Cytotoxicity with different concentrations of drugs was examined by methyl thiazolyl tetrazolium (MTT) method and ID50 value was calculated.
RESULTS: Autoradiographic bands showed that β-LPA inhibited the replication of HBV DNA in a dose-dependent manner. ED50 value was 0.01 μmol/L. Cytotoxicity experiment showed that the ID50 value of β-LPA was 50 μmol/L. The contents of HBsAg and HBeAg were decreased in a concentration-dependent manner. β-LPA at a low concentration had no marked effect on HBsAg and HBeAg in supernate.
CONCLUSION: β-LPA possesses potent inhibitory effect on the replication of HBV in vitro with little cytotoxicity.
Collapse
|
9
|
He XX, Lin JS, Chang Y, Zhang YH, Li Y, Wang XY, Xu D, Cheng XM. Effects of two novel nucleoside analogues on different hepatitis B virus promoters. World J Gastroenterol 2008; 14:1836-41. [PMID: 18350620 PMCID: PMC2701512 DOI: 10.3748/wjg.14.1836] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To explore the effects of the nucleoside analogues β-L-D4A and β-LPA on hepatitis B virus (HBV) promoters.
METHODS: Four HBV promoters were amplified by polymerase chain reaction (PCR) and subcloned into the expression vector pEGFP-1. The four recombinants controlled by HBV promoters were confirmed by restriction analysis and sequencing. Human hepatoma HepG2 cells transfected with the recombinant plasmids were treated with various concentrations of β-L-D4A and β-LPA. Then, enhanced green fluorescent protein (EGFP)-positive cells were detected by fluorescence microscopy and using a fluorescence activated cell sorter (FACS).
RESULTS: Four HBV promoters were separately obtained and successfully cloned into pEGFP-1. Expression of EGFP under the control of the surface promoter (Sp) and the X promoter (Xp) was inhibited by β-L-D4A in a dose-dependent manner, while expression of EGFP under the control of the core promoter (Cp) and Xp was inhibited by β-LPA in a dose-dependent manner.
CONCLUSION: The two novel nucleoside analogues investigated here can inhibit the activities of HBV promoters in a dose-dependent manner. These findings may explain the mechanisms of action by which these two novel compounds inhibit HBV DNA replication.
Collapse
|
10
|
He XX, Chen T, Lin JS, Chang Y, Ye BX. Inhibition of the replication of hepatitis B virus in vitro by a novel 2,6-diaminopurine analog, beta-LPA. Biochem Biophys Res Commun 2008; 369:513-8. [PMID: 18284916 DOI: 10.1016/j.bbrc.2008.02.039] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2008] [Accepted: 02/12/2008] [Indexed: 12/16/2022]
Abstract
Antiviral therapy of chronic hepatitis B remains a major clinical problem worldwide. Like lamivudine, nucleoside analogs have become the focus of investigation of anti-hepatitis B virus (anti-HBV) drugs. Here, beta-LPA is a novel 2,6-diaminopurine analog found to possess potent anti-HBV activity. In HepG2.2.15 cell line, beta-LPA had a 50% effective concentration (EC(50)) of 0.01 microM against HBV, as determined by analysis of secreted and intracellular episomal HBV DNA. Levels of HBV surface antigen (HBsAg) and e antigen (HBeAg) in drug-treated cultures revealed that beta-LPA had no significant inhibitory effects on HBsAg and HBeAg. beta-LPA didn't show any cytotoxicity up to 0.4 microM with a 50% cytotoxic concentration (CC(50)) of 50 microM. Furthermore, treatment with beta-LPA resulted in no apparent inhibitory effects on mitochondrial DNA content. Considering the potent inhibition of HBV DNA synthesis and no obvious toxicity of beta-LPA, this compound should be further explored for development as an anti-HBV drug.
Collapse
Affiliation(s)
- Xing-Xing He
- Institute of Liver Diseases, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | | | | | | | | |
Collapse
|
11
|
Amir-Kroll H, Riveron L, Sarmiento ME, Sierra G, Acosta A, Cohen IR. A conjugate vaccine composed of a heat shock protein 60 T-cell epitope peptide (p458) and Neisseria meningitidis type B capsular polysaccharide. Vaccine 2006; 24:6555-63. [PMID: 16843573 DOI: 10.1016/j.vaccine.2006.06.019] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2005] [Revised: 06/12/2006] [Accepted: 06/14/2006] [Indexed: 11/26/2022]
Abstract
Neisseria meningitidis type B is a major world-health problem. The Meningococcus type B capsular polysaccharide (MnB) is very poorly immunogenic and no vaccine to the antigen exists. Here, we conjugated the MnB to a T-cell carrier peptide (p458) derived from the self-60kDa heat shock protein molecule. The conjugate vaccine was effective in inducing long-lasting IgG antibodies to the MnB antigen in mice. The vaccine was also immunogenic when injected in PBS. Thus, the p458 carrier peptide can induce T-cell help for the switch to IgG Ab to the MnB antigen.
Collapse
Affiliation(s)
- Hila Amir-Kroll
- Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel
| | | | | | | | | | | |
Collapse
|
12
|
Abstract
Dengue is one of the most important mosquito-borne viral disease causing dengue fever and/or dengue shock syndrome/haemorrhagic fever. In some reports, the non-structural protein 1 (NS1) has been identified as a promising antigen for the development of vaccines against dengue virus (DENV). Apparently, it can elicit a protective antibody response with complement-fixing activities. In order to investigate the potential of a DNA vaccine based on the NS1 protein against DENV, we used the plasmid pcTPANS1, which contains the secretory signal sequence derived from human tissue plasminogen activator (t-PA) fused to the full length of the DENV-2 NS1 gene. All Balb/c mice intramuscularly inoculated with the pcTPANS1 presented high levels of NS1-specifc antibodies. Vaccinated animals were challenged with intracerebral DENV-2 virus inoculations and a 100% survival was observed. In general, results demonstrate that the pcTPANS1 plasmid is able to induce protection in mice, and then may be used as a vaccination approach against DENV in further assays.
Collapse
Affiliation(s)
- S M Costa
- Laboratório de Imunopatologia, Departamento de Bioquímica e Biologia Molecular, IOC, Fundação Oswaldo Cruz (FIOCRUZ), Av. Brazil 4365, Pav. Leonidas Deane, Sala 204, Rio de Janeiro, RJ CEP 21045-900, Brazil
| | | | | |
Collapse
|
13
|
Costa SM, Paes MV, Barreto DF, Pinhão AT, Barth OM, Queiroz JLS, Armôa GRG, Freire MS, Alves AMB. Protection against dengue type 2 virus induced in mice immunized with a DNA plasmid encoding the non-structural 1 (NS1) gene fused to the tissue plasminogen activator signal sequence. Vaccine 2005; 24:195-205. [PMID: 16122850 DOI: 10.1016/j.vaccine.2005.07.059] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2005] [Accepted: 07/25/2005] [Indexed: 12/01/2022]
Abstract
Dengue is one of the most important arboviral diseases in humans, and although efforts over the last decades have dealt with the development of a vaccine, this vaccine is not available yet. In order to evaluate the potential of a DNA vaccine based on the non-structural 1 (NS1) protein against dengue virus (DENV), we constructed the pcTPANS1 plasmid which contains the secretory signal sequence derived from human tissue plasminogen activator (t-PA) fused to the full length of the DENV-2 NS1 gene. Results indicate that pcTPANS1 promotes correct expression of NS1 in eukaryotic cells and drives secretion of the recombinant protein to the surrounding medium in a dimeric form. Balb/c mice, intramuscularly inoculated with this plasmid, presented high levels of antibodies, recognizing mainly surface-exposed conformational epitopes present in the NS1 protein expressed by insect cells. Long-term antibody response was observed in animals 56 weeks after the first plasmid inoculation, and a rapid, efficient secondary response was observed after a DNA boost. Vaccinated animals were challenged against DENV-2 in two murine models, based on intracerebral (i.c.) and intraperitoneal (i.p.) virus inoculations, and in both cases, pcTPANS1-immunized mice were protected. Overall, these results provide further support for the use of such a plasmid in a possible approach for the development of a vaccine against DENV.
Collapse
Affiliation(s)
- Simone M Costa
- Department of Biochemistry and Molecular Biology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Av. Brazil 4365, Pav. Leonidas Deane, sala 204, Rio de Janeiro, RJ, CEP 21040-900, Brazil
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Torres AG, Zhou X, Kaper JB. Adherence of diarrheagenic Escherichia coli strains to epithelial cells. Infect Immun 2005; 73:18-29. [PMID: 15618137 PMCID: PMC538947 DOI: 10.1128/iai.73.1.18-29.2005] [Citation(s) in RCA: 161] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Alfredo G Torres
- Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555-1070, USA.
| | | | | |
Collapse
|
15
|
Wang SH, Syu WJ, Hu ST. Identification of the homotypic interaction domain of the core protein of dengue virus type 2. J Gen Virol 2004; 85:2307-2314. [PMID: 15269372 DOI: 10.1099/vir.0.80067-0] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Dengue virus causes dengue haemorrhagic fever or dengue shock syndrome with a high mortality rate. The genome of dengue virus is a positive-sense, single-stranded RNA encoding three structural and seven non-structural proteins. The core protein is one of the three structural proteins and is the building block of the nucleocapsid of dengue virus. The core protein of dengue virus type 2 (DEN2) is composed of 100 aa with four alpha-helix domains. An internal hydrophobic domain located at aa 44-60 was identified. The DEN2 core protein was shown to form homodimers. Deletion of aa 1-36 or 73-100 decreased but did not completely abolish the core-to-core homotypic interaction, whereas deletion of a portion (aa 44-60) within aa 37-72 completely abolished the ability of the DEN2 core proteins to interact with each other. A recombinant DEN2 core protein corresponding to aa 37-72 was able to undergo homotypic interaction and bound to a native DEN2 core protein. The results of this study indicated that the homotypic interaction domain of the DEN2 core protein is located at aa 37-72 and that the internal hydrophobic domain located at aa 44-60 plays a pivotal role in core-to-core homotypic interaction.
Collapse
Affiliation(s)
- Shao-Hung Wang
- Institute of Microbiology and Immunology, School of Life Science, National Yang-Ming University, Taipei, Taiwan, Republic of China
| | - Wan-Jr Syu
- Department of Microbiology and Immunology, School of Medicine, National Yang-Ming University, Taipei, Taiwan, Republic of China
- Institute of Microbiology and Immunology, School of Life Science, National Yang-Ming University, Taipei, Taiwan, Republic of China
| | - Shiau-Ting Hu
- Department of Microbiology and Immunology, School of Medicine, National Yang-Ming University, Taipei, Taiwan, Republic of China
- Institute of Microbiology and Immunology, School of Life Science, National Yang-Ming University, Taipei, Taiwan, Republic of China
| |
Collapse
|